Nanocapsules, nanoemulsion and nanodispersion containing melatonin: Preparation, characterization and stability evaluation

Pharmazie

Volumn 62, Issue 5, 2007, Pages 354-360

  Schaffazick, S R ^a   Pohlmann, A R ^a   Guterres, Sílvia S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EUDRAGIT; EUDRAGIT RS; MELATONIN; NANOCAPSULE; NANOPARTICLE; POLYCAPROLACTONE;

ANTIOXIDANT ACTIVITY; ARTICLE; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; EMULSION; NANOTECHNOLOGY; PARTICLE SIZE; PH MEASUREMENT; PHYSICAL CHEMISTRY; ROOM TEMPERATURE; TEMPERATURE SENSITIVITY;

ANTIOXIDANTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG STABILITY; EMULSIONS; HYDROGEN-ION CONCENTRATION; MELATONIN; METHACRYLATES; NANOCAPSULES; PARTICLE SIZE; POLYESTERS; POLYMETHACRYLIC ACIDS; TEMPERATURE;

EID: 34249806996     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.5.6087     Document Type: Article

References (49)

1. Abdelwahed W, Degobert G, Fessi H (2006) A pilot study of freeze-drying of poly(ε-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int J Pharm 309: 178-188.
2. Allémann E, Leroux J-C, Gurny R (1998) Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 34: 171-189.
3. Andrisano V, Bertucci C, Battaglia A, Cavrine (2000) Photostability of drugs: photodegradation of melatonin and its determination in commercial formulations. J Pharm Biomed Anal 23: 15-23.
4. Barrenetxe J, Delagrange P, Martínez JA (2004) Physiological and metabolic functions of melatonin. J Physiol Biochem 60: 61-72.
5. Bénès L, Claustrat B, Horrière F, Geoffriau M, Konsil J, Parrott KA, DeGrande G, McQuinn RL, Ayres JW (1997) Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: A crossover study with melatonin. J Pharm Sci 86: 1115-1119.
6. Calvo P, Vila-Jato JL, Alonso MJ (1996) Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules and nanoemulsions, as ocular drug carriers. J Pharm Sci 85: 530-536.
7. Cavallo A, Hassan M (1995) Stability of melatonin in aqueous solution. J Pineal Res 18: 90-92.
8. Couvreur P, Barrat G, Fattal E, Legrand P, Vauthier C (2002) Nanocapsule technology: A review. Crit Rev Ther Drug Carrier Syst 19: 99-134.
9. Cuzzocrea S, Reiter RJ (2001) Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur J Pharmacol 426: 1-10.
10. Daya S, Walker RB, Glass BD, Anoopkumar-Dukie S (2001) The effect of variations in pH and temperature on stability of melatonin in aqueous solution. J Pineal Res 31: 155-158.
11. El-Gibaly I (2002) Development and in vitro evaluation of novel floating chitosan microcapsules for oral uso: comparison with non-floating chitosan microspheres. Int J Pharm 249: 7-21.
12. El-Gibaly I, Meki AMA, Abdel-Ghaffar SK (2003) Novel B melatonin-loaded chitosan microcapsules: in vitro characterization and antiapoptosis efficacy for aflatoxin B1-induced apoptosis in rat liver. Int J Pharm 260: 5-22.
13. Esquifino AI, Pandi-Perumal SR, Cardinali DP (2004) Circadian organization of the immune response: A role for melatonin. Clin Applied Immunol Rev 4: 423-433.
14. Epstein FH (1997) Mechanisms of disease-melatonin in humans. New Engl J Med 336: 186-195.
15. Ferranti V, Marchais H, Chabenat C, Orecchioni AM, Lafont O (1999) Primidone-loaded poly-ε-caprolactone nanocapsules: incorporation efficiency and in vitro release profiles. Int J Pharm 193: 107-111.
16. Fessi H, Puisieux F, Devissaguet JPh, Ammory N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55: r1-r4.
17. Gupta M, Aneja S, Kohli K (2004) Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind placebo-controlled trial. Epilepsy Behav 5: 316-321.
18. Guterres SS, Fessi H, Barratt G, Puisieux F, Devissaguet J-P (1995a) Poly(D,L-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Pharm Res 12: 1-3.
19. Guterres SS, Fessi H, Barratt G, Devissaguet J-P, Puisieux P (1995b) Poly(DL-lactide) nanocapsules containing diclofenac: I. Formulation and stability study. Int J Pharm 113: 57-63.
20. Guterres SS, Muller CR, Michalowski CB, Pohlmann AR, Dalla Costa T (2001) Gastro-intestinal tolerance following oral administration of spray-dried diclofenac-loaded nanocapsules and nanospheres. STP Pharma Sci 11: 229-233.
21. Kandimalla KK, Kanikkannan N, Singh M (1999) Optimization of a vehicle mixture for the transdermal delivery of melatonin using artificial neural networks and response surface method. J Control Release 61: 71-82.
22. Kirby AW, Clayton M, Rivera P, Comperatore CA (1999) Melatonin and the reduction or alleviation of stress. J Pineal Res 27: 78-85.
23. Kumar A, Agarwal SP, Khanna R (2003) Modified release bi-layered tablet of melatonin using β-cyclodextrin. Pharmazie 58: 642-644.
24. Lacoulonche F, Gamisans F, Chauvet A, García ML, Espina M, Egea MA (1999) Stability and in vitro drug release of flurbiprofen-loaded poly-ε-caprolactone nanospheres. Drug Dev Ind Pharm 25: 983-993.
25. Lee B-J, Parrot KA, Ayres JW, Sack RL (1995) Design and evaluation of an oral controlled release delivery system form melatonin in human subjects. Int J Pharm 124: 119-127.
26. Lee B-J, Mim G-H (1996a) Oral controlled release of melatonin using polymer-reinforced and coated alginate beads. Int J Pharm 144: 37-46.
27. Lee B-J, Parrot KA, Ayres JW, Sack RL (1996b) Development and characterization of an oral controlled-release delivery system for melatonin. Drug Dev Ind Pharm 22: 269-274.
28. Lee B-J, Choe JS, Kim C-K (1998) Preparation and characterization of melatonin-loaded stearyl alcohol microspheres. J Microencapsul 15: 775-787.
29. Lee B-J, Ryu S-G, Cui J-H (1999) Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev Ind Pharm 25: 493-501.
30. Legrand P, Barrat G, Mosqueira V, Fessi H, Devissaguet JP (1999) Polymeric nanocapsules as drug delivery systems: A review. STP Pharma Sci 9: 411-418.
31. Losa C, Marchal-Heussler L, Orallo F, Vila Jato, JL, Alonso MJ (1993) Design of new formulations for topical ocular administration: Polymeric Nanocapsules containing metipranolol. Pharm Res 10: 80-87.
32. Maharaj DS, Anoopkumar-Dukie S, Glass BD, Antunes EM, Lack B, Walker RB, Daya S (2002) The identification of the UV degradants of melatonin and their ability to scavenge free radicals. J Pineal Res 32: 257-261.
33. Mao S, Chen J, Wei Z, Liu H, Bi D (2004) Intranasal administration of melatonin starch microspheres. Int J Pharm 272: 37-43.
34. Matsubara E, Shoji M, Murakami T, Kawarabayashi T, Abe K (2003) Alzheimer's disease and melatonin. Int Congr Ser 1252: 395-398.
35. Molpeceres J, Aberturas MR, Chacón M, Berges L, Guzmán, M (1997) Stability of cyclosporine-loaded poly-ε-caprolactone nanoparticles. J Microencapsul 14: 777-787.
36. Müller CR, Schaffazick S.R, Pohlmann AR, Freitas LL, Silveira P, Costa TD, Guterres SS (2001) Spray-dried diclofenac-loaded poly(E-caprolactone) nanocapsules and nanospheres. Preparation and physicochemical characterization. Pharmazie 56: 864-867.
37. Nishida S, Segawa T, Murai I, Nakagawa S (2002) Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Δ-5 desaturase activity. J Pineal Res 32: 26-33.
38. Palumbo M, Russo A, Cardile V, Renis M, Paolino D, Puglisi G, Fresta M (2002) Improved antioxidant effect of idobenone-loaded polyethyl-2-cyanacrylate nanocapsules tested on human fibroblasts. Pharm Res 19: 71-78.
39. Pohlmann AR, Weiss V, Mertins O, Pesce da Silveira N, Guterres SS (2002) Spray-dried indomethacin-loaded polyester nanocapsules and nanospheres: development, stability evaluation and nanostructure models. Eur J Pharm Sci 16: 305-312.
40. Reiter R, Tang L, Garcia JJ, Muñoz-Hoyos A (1997) Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 60: 2255-2271.
41. Reiter RJ (2003) Melatonin: clinical relevance. Best Pract Res Clin Endoc Metab 17: 273-285.
42. Schaffazick SR, Guterres SS, Lucca-Freitas L, Pohlmann AR (2003a) Caracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. Quim Nova 26: 726-737.
43. Schaffazick SR, Pohlmann AR, Dalla-Costa T, Guterres SS (2003b) Freeze-drying polymeric colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study. Eur J Pharm Biopharm 56: 501-505.
44. Schaffazick SR, Pohlmann AR, de Cordova CAS, Creczynski-Pasa TB, Guterres SS (2005) Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int J Pharm 289: 209-213.
45. Schaffazick SR, Pohlmann AR, Mezzalira G, Guterres SS. (2006) Development of nanocapsule suspensions and nanocapsule spray-dried powders containing melatonin. J Braz Chem Soc 17: 562-569.
46. Siegrist C, Benedetti C, Orlando A, Beltrán JM, Tuchscherr L, Noseda MJ, Brusco LI, Cardinali DC (2001) Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30: 34-42.
47. Teixeira M, Alonso MJ, Pinto MMM, Barbosa CM (2005) Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm 59: 491-500.
48. Tursilli R, Casolari A, Iannuccelli V, Scalia S (2006) Enhancement of melatonin photostability by encapsulation in lipospheres. J Pharm Biomed Anal 40: 910-914.
49. Vijayalaxmi, Reiter RJ, Tan D-X, Herman TS, Thomas CR (2004) Melatonin as a radioprotective agent: a review. Int J Rad Oncol Biol Phys 59: 639-653.